enGene Holdings Inc.

Equities

ENGN

CA29286M1059

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
9 ^USD	-10.00%		-9.09%	-2.49%

14/06	EnGene Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
15/05	EnGene Holdings Inc. Approves Board Appointments	CI

EnGene Holdings Inc. Announces Resignation of Jason Hanson as Member of the Board of Directors

February 14, 2024 at 05:15 pm IST

enGene Holdings Inc. announced that due to personal family and health reasons, Jason Hanson intends to resign from his role as member of the board of directors. Following the hiring of a new CEO, he will support the company and the new CEO as a strategic advisor.

Latest news about enGene Holdings Inc.

EnGene Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	14/06	CI
EnGene Holdings Inc. Approves Board Appointments	16/05	CI
Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target	22/04	MT
Guggenheim Starts enGene Holdings With Buy Rating, $34 Price Target	15/04	MT
EnGene Holdings Inc. Appoints Raj Pruthi as SVP, Urologic Oncology and Clinical Development	09/04	CI
UBS Initiates Coverage on enGene Holdings With Buy Rating, $37 Price Target	28/03	MT
EnGene Holdings Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	12/03	CI
Morgan Stanley Starts Coverage on Engene With Overweight Rating, $40 Price Target	08/03	MT
Leerink Partners Starts enGene Holdings With Outperform Rating, $31 Price Target	20/02	MT
EnGene Holdings Inc. announced that it has received CAD 200 million in funding from a group of investors	20/02	CI
Top Midday Gainers	15/02	MT
EnGene Holdings Inc. Announces Resignation of Jason Hanson as Member of the Board of Directors	14/02	CI
EnGene Holdings Inc. Announces Resignation of Jason Hanson as Chief Executive Officer	14/02	CI
EnGene Holdings Inc. announced that it expects to receive CAD 200 million in funding from a group of investors	14/02	CI
EnGene Holdings Inc. Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary	30/01	CI
EnGene Holdings Inc. Together with Its Subsidiaries, Engene Inc. and Engene USA, Inc. Enters into an Amended and Restated Loan and Security Agreement	29/12	CI
EnGene Holdings Inc. Announces Expanded $50 Million Debt Facility with Hercules Capital	23/12	CI
EnGene Holdings Inc. announced that it expects to receive $50 million in funding	22/12	CI
EnGene Holdings Inc. Appoints Lota S. Zoth as Member of the Board of Directors and Audit Committee Chair	20/12	CI
EnGene Holdings Inc Appoints Ryan Daws as Head of Business Development	29/11	CI
EnGene Holdings Inc. Appoints Ryan Daws as Chief Financial Officer	29/11	CI

Chart enGene Holdings Inc.

Duration

Period

More charts

Company Profile

enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Companyâs proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Companyâs DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.36 USD

Average target price

33 USD

Spread / Average Target

+294.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENGENE HOLDINGS INC.	-2.49%	369M
MODERNA, INC.	+34.01%	51.07B
LONZA GROUP AG	+33.84%	38.86B
IQVIA HOLDINGS INC.	-8.02%	38.78B
CELLTRION, INC.	-8.98%	26.69B
ICON PUBLIC LIMITED COMPANY	+12.56%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-19.62%	19.46B
UNITED THERAPEUTICS CORPORATION	+39.18%	13.58B
MEDPACE HOLDINGS, INC.	+31.47%	12.46B
BIO-TECHNE CORPORATION	-3.40%	11.75B

Other Biotechnology & Medical Research